Is Alnylam (ALNY) One of the Best Aggressive Growth Stocks to Buy?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts. On May 5, H.C. Wainwright reaffirmed its Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a price target of $510 on the stock. This update came after the company reported Q1 results.

The company reported total net product revenue of $1.036 billion for Q1 2026, up 121% year-over-year. H.C. Wainwright had estimated $1.071 billion. During the quarter, the company’s transthyretin (TTR) franchise brought in $910.4 million in revenue, an increase of 153% year-over-year. However, this also came in under H.C. Wainwright’s expectation of $929.1 million.

The research firm noted that Alnylam Pharmaceuticals, Inc.’s (NASDAQ:ALNY) drug AMVUTTRA is approaching parity with Pfizer’s VYNDAMAX in new patient starts for transthyretin amyloidosis with cardiomyopathy, based on the company’s own estimates.

The company kept its full-year 2026 total net product revenue guidance range between $4.90 billion to $5.30 billion. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) also reiterated revenue guidance for the TTR franchise between $4.40 billion and $4.70 billion. At the midpoint, this implies 83% year-over-year growth.

As of March 31, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had $3.0 billion in cash. The company expects several upcoming catalysts this year, including updates from its ongoing Phase 3 ZENITH trial for zilebesiran.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a global biopharmaceutical company that is widely known as the leader in RNA interference (RNAi) therapeutics. It focuses on developing transformative therapies with the potential to prevent, halt, or reverse rare and prevalent diseases.

READ NEXT: 10 Mid-Cap Stocks That Are On Fire Right Now and 10 Best US Stocks Under $5 to Buy.

Disclosure: None.  Follow Insider Monkey on Google News.